Metformin for the Treatment of Hidradenitis Suppurativa (HS)
NCT ID: NCT04649502
Last Updated: 2023-10-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
62 participants
INTERVENTIONAL
2021-01-25
2023-08-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparative Study of Metformin Versus Doxycycline in Moderate to Severe Adult Acne Vulgaris Patients.
NCT06252194
Trial Comparing Efficacy of Treatments for Hidradenitis Suppurativa
NCT01063270
Effect of Sclerotherapy on Fistulas and Sinus Tracts in Hidradenitis Suppurativa
NCT02805595
A Study to Test the Efficacy and Safety of SAR442970 in Adults With Hidradenitis Suppurativa
NCT05849922
To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa
NCT04476043
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Metformin combined with doxycycline
Metformin
Metformin in combination with doxycycline
Doxycyline combined with placebo
Metformin
Metformin in combination with doxycycline
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Metformin
Metformin in combination with doxycycline
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* A diagnosis of HS for at least 1 year prior to baseline
* mild to moderately active disease defined by a HS Physician Global Assessment (HS-PGA) score of 2-3 and the Refined Hurley classification of mild to moderate at baseline
* Indication for systemic therapy; i.e. uncontrolled disease under conventional topical therapy.
* Able and willing to give written informed consent and to comply with the study requirements
Exclusion Criteria
* Concomitant diabetes mellitus
* Use of antibiotics within 14 days prior to baseline
* Use of immunosuppressing/modulating therapies within 28 days prior to baseline
* A known allergy to metformin or doxycycline or any of the ingredients metformin or doxycycline
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
K.R. van Straalen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
K.R. van Straalen
MD.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Erasmus MC
Rotterdam, , Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EMCD20022
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.